127 related articles for article (PubMed ID: 34800879)
1. Novel combination therapy of prostate cancer cells with arsenic trioxide and flutamide: An in-vitro study.
Mirzaei A; Akbari MR; Tamehri Zadeh SS; Khatami F; Mashhadi R; Aghamir SMK
Tissue Cell; 2022 Feb; 74():101684. PubMed ID: 34800879
[TBL] [Abstract][Full Text] [Related]
2. Human prostate cancer cell epithelial-to-mesenchymal transition as a novel target of arsenic trioxide and curcumin therapeutic approach.
Mirzaei A; Jahanshahi F; Khatami F; Reis LO; Aghamir SMK
Tissue Cell; 2022 Jun; 76():101805. PubMed ID: 35487055
[TBL] [Abstract][Full Text] [Related]
3. Combined anticancer effects of simvastatin and arsenic trioxide on prostate cancer cell lines via downregulation of the VEGF and OPN isoforms genes.
Mirzaei A; Rashedi S; Akbari MR; Khatami F; Aghamir SMK
J Cell Mol Med; 2022 May; 26(9):2728-2740. PubMed ID: 35366048
[TBL] [Abstract][Full Text] [Related]
4. The effect of Ganoderma lucidum polysaccharide extract on sensitizing prostate cancer cells to flutamide and docetaxel: an in vitro study.
Rahimnia R; Akbari MR; Yasseri AF; Taheri D; Mirzaei A; Ghajar HA; Farashah PD; Baghdadabad LZ; Aghamir SMK
Sci Rep; 2023 Nov; 13(1):18940. PubMed ID: 37919464
[TBL] [Abstract][Full Text] [Related]
5. The effect of mesenchymal stem cells-derived exosomes on the prostate, bladder, and renal cancer cell lines.
Rezaeian A; Khatami F; Heidari Keshel S; Akbari MR; Mirzaei A; Gholami K; Mohammadi Farsani R; Aghamir SMK
Sci Rep; 2022 Dec; 12(1):20924. PubMed ID: 36463254
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide and BIBR1532 synergistically inhibit breast cancer cell proliferation through attenuation of NF-κB signaling pathway.
Nasrollahzadeh A; Bashash D; Kabuli M; Zandi Z; Kashani B; Zaghal A; Mousavi SA; Ghaffari SH
Life Sci; 2020 Sep; 257():118060. PubMed ID: 32645343
[TBL] [Abstract][Full Text] [Related]
7. RGD-decorated nanoliposomes for combined delivery of arsenic trioxide and curcumin to prostate cancer cells.
Khosravani F; Amiri F; Mahmoudi R; Morshedi D; Kobarfard F; Alipour M; Hosseini E; Bardania H
Naunyn Schmiedebergs Arch Pharmacol; 2024 Apr; 397(4):2347-2357. PubMed ID: 37831114
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide and Erlotinib loaded in RGD-modified nanoliposomes for targeted combination delivery to PC3 and PANC-1 cell lines.
Khosravani F; Mir H; Mirzaei A; Kobarfard F; Bardania H; Hosseini E
Biotechnol Appl Biochem; 2023 Apr; 70(2):811-823. PubMed ID: 36070882
[TBL] [Abstract][Full Text] [Related]
9. Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells.
Kai L; Levenson AS
Anticancer Res; 2011 Oct; 31(10):3323-30. PubMed ID: 21965742
[TBL] [Abstract][Full Text] [Related]
10. Combination of Arsenic Trioxide and Valproic Acid Efficiently Inhibits Growth of Lung Cancer Cells via G2/M-Phase Arrest and Apoptotic Cell Death.
Park HK; Han BR; Park WH
Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32290325
[TBL] [Abstract][Full Text] [Related]
11. Survivin mediates resistance to antiandrogen therapy in prostate cancer.
Zhang M; Latham DE; Delaney MA; Chakravarti A
Oncogene; 2005 Apr; 24(15):2474-82. PubMed ID: 15735703
[TBL] [Abstract][Full Text] [Related]
12. Combination of bifunctional alkylating agent and arsenic trioxide synergistically suppresses the growth of drug-resistant tumor cells.
Lee PC; Kakadiya R; Su TL; Lee TC
Neoplasia; 2010 May; 12(5):376-87. PubMed ID: 20454509
[TBL] [Abstract][Full Text] [Related]
13. Effects of the antiandrogen flutamide on the expression of protein kinase C isoenzymes in LNCaP and PC3 human prostate cancer cells.
Montalvo L; Carmena MJ; Bolaños O; Rodríguez-Henche N; Sánchez-Chapado M; Prieto JC
Biosci Rep; 2004 Feb; 24(1):11-21. PubMed ID: 15499829
[TBL] [Abstract][Full Text] [Related]
14. Combined arsenic trioxide-cisplatin treatment enhances apoptosis in oral squamous cell carcinoma cells.
Nakaoka T; Ota A; Ono T; Karnan S; Konishi H; Furuhashi A; Ohmura Y; Yamada Y; Hosokawa Y; Kazaoka Y
Cell Oncol (Dordr); 2014 Apr; 37(2):119-29. PubMed ID: 24599717
[TBL] [Abstract][Full Text] [Related]
15. Differential anticancer activities of arsenic trioxide on head and neck cancer cells with different human papillomavirus status.
Du S; Liu K; Gao P; Li Z; Zheng J
Life Sci; 2018 Nov; 212():182-193. PubMed ID: 30243648
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cells.
Chiu HW; Chen YA; Ho SY; Wang YJ
PLoS One; 2012; 7(2):e31579. PubMed ID: 22363680
[TBL] [Abstract][Full Text] [Related]
17. Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition.
Tamaki H; Harashima N; Hiraki M; Arichi N; Nishimura N; Shiina H; Naora K; Harada M
Oncotarget; 2014 Nov; 5(22):11399-412. PubMed ID: 25333266
[TBL] [Abstract][Full Text] [Related]
18. Activation of PPARγ intensified the effects of arsenic trioxide in acute promyelocytic leukemia through the suppression of PI3K/Akt pathway: Proposing a novel anticancer effect for pioglitazone.
Esmaeili S; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Salari S; Gharehbaghian A; Hamidpour M; Bashash D
Int J Biochem Cell Biol; 2020 May; 122():105739. PubMed ID: 32169580
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of PI3K pathway using BKM120 intensified the chemo-sensitivity of breast cancer cells to arsenic trioxide (ATO).
Alipour F; Riyahi N; Safaroghli-Azar A; Sari S; Zandi Z; Bashash D
Int J Biochem Cell Biol; 2019 Nov; 116():105615. PubMed ID: 31539632
[TBL] [Abstract][Full Text] [Related]
20. Biocompatible arsenic trioxide nanoparticles induce cell cycle arrest by p21(WAF1/CIP1) expression via epigenetic remodeling in LNCaP and PC3 cell lines.
Jadhav V; Ray P; Sachdeva G; Bhatt P
Life Sci; 2016 Mar; 148():41-52. PubMed ID: 26883975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
